
Zoetis (ZTS) Stock Forecast & Price Target
Zoetis (ZTS) Analyst Ratings
Bulls say
Zoetis has demonstrated significant growth in its Petcare division, evidenced by a remarkable increase in enrollment in the Zoetis Petcare Rewards program, which surged from 708,000 participants in 2018 to 2.5 million in the most recent reporting period, supported by over $120 million in investments made in 2023. The company's revenue from its flagship product, Simparica, reached $356 million in Q3, showing a year-over-year growth of 7%, while key dermatology products also contributed positively with a combined global revenue of $469 million, reflecting a 3% increase year-over-year. This robust performance in both revenue growth and strategic investments in customer engagement highlights Zoetis's strong market position and continuing momentum in the animal health sector.
Bears say
Zoetis has revised its revenue guidance for 2025 downward to a range of $9.400 billion to $9.475 billion, reflecting a decline in expected organic operational growth from previous estimates. The company experienced an 11% year-over-year decline in its osteoarthritis pain business due to negative publicity regarding the safety profile of its product, Librela, which has contributed to overall sales pressures. Additionally, the company's Q3'25 results fell below expectations, showing stagnation in the key companion animal health segment, driven by increased competition and a decline in veterinary clinic visits, further indicating challenges in maintaining revenue growth.
This aggregate rating is based on analysts' research of Zoetis and is not a guaranteed prediction by Public.com or investment advice.
Zoetis (ZTS) Analyst Forecast & Price Prediction
Start investing in Zoetis (ZTS)
Order type
Buy in
Order amount
Est. shares
0 shares